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The production of extended-spectrum beta-lactamases (ESBL) is considered one of the most important 
resistance mechanisms that impair antimicrobial treatment of infections caused by Enterobacteriaceae. 
Data on culture and susceptibility tests were collected from the Clinical Analyses and Research Laboratory 
charts reporting on patients admitted to the University Hospital of Maringá (HUM) from January 2004 
to December 2009. The following Enterobacteriaceae were selected: Escherichia coli, Klebsiella 
pneumoniae, Klebsiella oxytoca, Enterobacter spp. and Proteus mirabilis. All tests were performed 
according to the recommendations of the Clinical and Laboratory Standards Institute (biochemical 
identification; susceptibility tests; initial screening and phenotypic confirmatory tests for ESBL). For 
Enterobacter spp. isolates, a disk approximation test was carried out, adding a cefepime disk. Seven 
hundred samples were analyzed, and E. coli was the most prevalent bacteria (n= 356). ESBLs were 
detected phenotypically in 7.3% of E. coli, 61.7% of K. pneumoniae, 33.3% of K. oxytoca, 7.1% of P. 
mirabilis, and 13.4% of Enterobacter spp samples. Overall ESBL prevalence reached 22% when all 
producers were taken together. Although HUM is considered a small-sized hospital, it showed high levels 
of resistance to antimicrobial agents, similar to those observed in bigger hospitals, which demonstrated 
the need for careful epidemiological surveillance.
Uniterms: Extended-spectrum β-lactamases. Enterobacteriaceae. Bacterial resistance. β-lactams.
A produção de beta-lactamases de espectro ampliado (ESBL) é considerada um dos mais importantes 
mecanismos de resistência aos antimicrobianos, o que dificulta o tratamento de infecções causadas por 
enterobactérias. Dados sobre cultura e testes de sensibilidade foram coletados das fichas do Laboratório 
de Ensino e Pesquisa de Análises Clínicas de pacientes atendidos no Hospital Universitário de Maringá 
(HUM), de janeiro de 2004 a dezembro de 2009. As enterobactérias escolhidas foram: Escherichia 
coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter spp. e Proteus mirabilis. Os testes foram 
realizados de acordo com as recomendações do CLSI (identificação bioquímica; testes de suscetibilidade; 
triagem e confirmação fenotípica de produção de ESBL). Para isolados de Enterobacter spp., utilizou-
se a técnica de disco aproximação, acrescentando um disco de cefepima. Setecentas amostras foram 
analisadas e E. coli foi a bactéria mais prevalente (n=356). ESBLs foram detectadas fenotipicamente 
em 7,3% das amostras de E. coli, 61,7% das de K. pneumoniae, 3,3% das de K. oxytoca, 7,1% das de P. 
mirabilis e em 13,4% das de Enterobacter spp. A prevalência geral de ESBL chegou a 22%, somando-
se todos os isolados produtores. O HUM, mesmo sendo considerado um hospital de pequeno porte, 
apresenta níveis altos de resistência a antimicrobianos, semelhantes àqueles observados em hospitais 
maiores, demonstrando a necessidade de cuidadosa vigilância epidemiológica.
Unitermos: β-lactamases de espectro estendido. Enterobacteriaceae. Resistência bacteriana. β-lactâmicos.
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INTRODUCTION
An important emerging resistance mechanism 
among Enterobacteriaceae is the production of extended-
spectrum beta-lactamases (ESBL), which turn these bacilli 
highly efficient in inactivating third-generation cephalo-
sporins, monobactams, and penicillins (Hawkey, 2008). 
Escherichia coli and Klebsiella pneumoniae are the main 
ESBL-producing bacteria, even though other members of 
the Enterobacteriaceae family, namely Proteus mirabilis, 
Enterobacter spp., Salmonella spp., and Serratia spp., may 
show such resistance, albeit with less frequency (Thom-
son, 2001; Chaudhary, Aggarwal, 2004).
ESBL-producing organisms are clinically relevant 
and remain an important cause of therapy failure when 
cephalosporins are used, even when the bacteria appear to 
be sensitive to these agents by routine susceptibility test-
ing (Paterson, Bonomo, 2005). Further, ESBL-producing 
bacteria are frequently resistant to many other non-beta-
lactam antibiotics, limiting the available therapeutic 
options (Rice, Bonomo, 2007). In addition, owing to the 
resistance mechanism in plasmidial genes, patients colo-
nized by or infected with ESBL-producing bacteria should 
be placed under contact supervision to avoid transmission 
of hospital infection (Siegel et al., 2006).
ESBL-producing Enterobacteriaceae have been 
a problem in most hospitals worldwide. Very high rates 
have been reported in Asia, especially in China (55%) 
and India (79%), including isolates from the community 
(Pitout, 2010). Although the frequency of isolation of these 
microorganisms in Brazil (10% for E. coli and 17% for 
Klebsiella spp.) is lower than that found in Asian countries, 
it has been higher than in the United States and Europe 
(Rossi, 2011).
The presence of this enzyme implies an increase in 
the use of carbapenems in patient’s treatment, so there is 
a greater likelihood of the emergence of carbapenemase-
producing bacteria, enzymes capable of hydrolyzing 
carbapenems (Pitout, 2010). The presence of Enterobacte-
riaceae which produce carbapenemases is already a reality 
in most hospitals (Nordmann et al., 2009). However, the 
emergence of such resistance in bacteria from community 
patients, as already reported, surely hampers its control 
(Nordmann et al., 2011).
During the last few years, some studies have dem-
onstrated that the breakpoints for cephalosporins, used by 
most laboratories, failed to detect many ESBL-producing 
Enterobacteriaceae (Wong-Beringer et al., 2002; Pater-
son, 2006). The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the Clinical and 
Laboratory Standards Institute (CLSI) have recently 
revised breakpoints for third-generation cephalosporin 
(Kahlmeter, 2008; CLSI, 2010). Until 2009, it had been 
recommended that, if ESBL production was confirmed, the 
laboratory must report all penicillins, cephalosporins and 
aztreonam as resistant, even though the susceptibility test 
showed sensitive results in vitro (CLSI, 2009). However, 
using the new breakpoints as recommended by CLSI, 
ESBL detection may be restricted for epidemiological or 
infection control purposes (CLSI, 2010).
Several phenotypic confirmatory tests for ESBL 
producers have been described in the literature. All 
methods utilize the characteristics of ESBL production 
inhibition by clavulanic acid. The CLSI recommended 
test consists of an initial screening test and a phenotypic 
confirmatory test. Susceptibilities to ceftazidime, ceftri-
axone, cefotaxime, cefpodoxime and aztreonam in the 
initial screening test are evaluated by disk diffusion or by 
the broth dilution method. A decrease in susceptibilities 
to one or more antibiotics tested may indicate produc-
tion of ESBLs and require the subsequent confirmatory 
test. This test is carried out using disk diffusion or broth 
dilution methods, and the performance of cefotaxime and 
ceftazidime in the presence and absence of clavulanate 
is evaluated (CLSI, 2010).
Resistance in Enterobacteriaceae remains a major 
problem in most hospitals in spite of the current debate on 
the relationship between minimum inhibitory concentra-
tions (MICs), detection of ESBL, and clinical results when 
third-generation cephalosporins are used.
The present study reports on ESBL production 
frequency among the commonest isolated Enterobacte-
riaceae in a public university hospital in Maringá (PR), 
Brazil, during a six-year period.
METHODS
Data on culture and susceptibility tests were col-
lected from the Clinical Analyses and Research Labora-
tory (LEPAC) charts reporting on patients admitted to 
the University Hospital of Maringá (HUM) from January 
2004 to December 2009. HUM is a small size hospital, 
with 120 beds, of which 20 belong to the intensive care 
units (ICUs), and the others are distributed among general, 
surgical, obstetric and pediatric units. Since 2003, HUM 
participates in the Projeto Hospital Sentinela and in the 
Rede de Monitoramento de Resistência – Agência Nacio-
nal de Vigilância Sanitária.
No personal data were retrieved from patients so that 
privacy could be warranted and law transgressions con-
cerning research with human beings avoided (Resolution 
196/96 Brazil National Health Council, Health Ministry). 
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The present study was submitted to and approved by the 
HUM’s Regulatory Commission of Academic Activities 
and Voluntary Services.
The Enterobacteriaceae selected for this study 
were: Escherichia coli, Klebsiella pneumoniae, Klebsiella 
oxytoca, Enterobacter spp., and Proteus mirabilis. These 
species were chosen since they are more frequent among 
the Enterobacteriaceae commonly detected in hospitals 
around the world (Baquero et al., 2009). Only one isolate 
from each bacterial species was selected per patient.
As part of LEPAC Clinical Bacteriology Sector 
routine, the bacterial isolates were biochemically identi-
fied and submitted to susceptibility tests, using AUTO-
SCAN-4 automated system (Siemens Microscan, Inc., 
Deerfield, IL, USA). The antimicrobials tested and the 
interpretation criteria were the ones recommended by the 
CLSI (CLSI, 2004-2010).
The selected Enterobacteriaceae that had MICs 
suggestive of ESBL production were submitted to confir-
matory tests by double disk diffusion (CLSI, 2004-2010). 
The disks used were of ceftazidime (30 mg), cefpodoxime 
(10 mg) and cefotaxime (30 mg) combined with clavulanate 
(10 mg), and disks containing only the referred cephalo-
sporins (Oxoid, Basingstoke, England). A ≥ 5 mm increase 
in growth inhibition zone for any antimicrobial associated 
with clavulanate in comparison with the inhibition zone 
of the antimicrobial tested alone confirmed ESBL produc-
tion. For Enterobacter spp. isolates, a disk approximation 
test was carried out (Tumbarello et al., 2004), adding a 
cefepime disk (30 mg; Oxoid Basingstoke, England).
RESULTS AND DISCUSSION
Increasing number of reports on bacteria resistant 
to beta-lactam antibiotics is a great concern since these 
drugs are frequently the primary arsenal for the treatment 
of bacterial infections. The detection of ESBL-producing 
bacteria isolated from clinical samples is highly important, 
since physicians may choose a probably more efficient 
treatment. Besides their resistance to penicillins, cephalo-
sporins and aztreonam, these pathogens are also frequently 
resistant to other classes of antimicrobial agents and thus 
limit therapeutic options (Rice & Bonomo, 2007).
Seven hundred Enterobacteriaceae isolated from 
clinical samples of patients admitted to different HUM 
units were studied, of which 356 (50.9%) were identified 
as E. coli, 167 (23.9%) as K. pneumoniae, 134 (19.1%) as 
Enterobacter spp., 28 (4.0%) as P. mirabilis, and 15 (2.1%) 
as K. oxytoca. When isolates from all species are taken 
into consideration, urine was the most frequent clinical 
source (Figure 1).
There was an overall prevalence of 22% of ESBL 
production among the bacteria studied. Although this 
number may be considered high, it is close to that dem-
onstrated in other Brazilian studies (Mendes et al., 2000; 
Nogueira et al., 2006).
The prevalence of ESBL-producing K. pneumoniae 
is high in many countries and of special concern in South 
American countries (Shah et al., 2004; Nogueira et al., 
2006; Reinert et al., 2007). K. pneumoniae isolates had the 
highest positiveness level for ESBL production in HUM 
(61.7%). The prevalence was high in almost every sector 
(Figure 2). One of the possible reasons for such high preva-
lence could be the fact that almost half of all K. pneumoniae 
isolated came from samples of ICU patients, including adult 
and pediatric ICUs. ESBL-producing bacteria were detected 
as important agents of bloodstream infection in pediatric 
ICU patients and contributed to high mortality rates re-
corded in these patients (Prabhu et al., 2010). Although the 
prevalence of ESBL-producing K. pneumoniae remained 
steady for the past few years (with no significant increase), 
its high prevalence in the hospitalized population becomes 
a constant threat due to the subsequent narrowest choice of 
effective antimicrobials.
 Although few K. oxytoca were isolated (15), 5 
(33.3%) revealed ESBL-production, with 1 isolate from 
the general unit, 2 from the ICU for adults and 2 in the 
pediatric ICU. High prevalence of ESBL-producing K. 
oxytoca, close to 30%, as seen in this and other studies 
(Peloso et al., 2003; Minarini et al., 2008), has been rare. 
Lower prevalence is usually observed, with values close to 
10% (Rossi et al., 2006; Coque et al., 2008). In fact, few K. 
oxytoca were isolated, and since 46% of all samples came 
from the ICUs, such high rate is justified.
FIGURE 1 - Number of bacterial isolates from HUM per type of 
biological source, between January 2004 and December 2009.
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FIGURE 2 - Percentage of isolates of ESBL-producing K. pneumoniae, per admittance unit in HUM, from January 2004 to 
December 2009.
Among Enterobacteriaceae, E. coli is one of the 
commonest species isolated in nosocomial infections 
(Baquero et al., 2009). Most E. coli were isolated from 
urine samples of outpatients attended at the emergency 
room (ER), with a total of 26 (7.3%) showing ESBL 
production. These patients stayed at the ER for a variable 
period of time until treatment was defined, and then were 
discharged. The pediatric ICU had the highest proportion 
of E. coli ESBL-producers and non-producers (Figure 3). 
The prevalence of ESBL-producing E. coli varies widely 
among countries, being <1% in some regions (Bradford, 
2001; Coque et al., 2008); however, higher rates, similar to 
FIGURE 3 - Percentage of isolates of ESBL-producing E. coli, per admittance unit in HUM, from January 2004 to December 2009.
those found in the present study, have also been reported, 
especially in Latin American countries (Reinert et al., 
2007; Baquero et al., 2009).
The high isolation rates of ESBL-producing E. 
coli in many countries, and hence the increasing use of 
carbapenems, highlight another public health issue: the 
emergence of carbapenemase-producing bacteria (Pitout, 
Laupland, 2008). Since E. coli is an important member of 
the human microbiota and agent of several kinds of noso-
comial and community infections, it is essential to detect 
and control these mechanisms of resistance (Nordmann 
et al., 2011)
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During the study period, Enterobacter spp. was 
isolated from 134 patients of all units, with urine as the 
commonest source (51.5%). The most prevalent species 
was E. cloacae (60.4%). Among the isolates, 8 E. aero-
genes and 10 E. cloacae were ESBL-producers, of which 9 
isolates came from patients admitted to the ICU for adults. 
The high number of ESBL-producing Enterobacter spp. 
found in the literature (Crowley, Ratcliffe, 2003; Rossi et 
al., 2006) demonstrates how important it is to suspect a 
resistance mechanism also in this genus. Nevertheless, it is 
more difficult to identify ESBL production in Enterobacter 
spp. In fact, the genus may also present AmpC chromoss-
omal enzyme, which, when induced by clavulanate, causes 
cephalosporin hydrolysis, as does ESBLs. Consequently, 
cefepime, a fourth-generation cephalosporin, is recom-
mended in confirmatory tests, since this drug is weakly 
degraded by AmpC chromossomal enzyme but destroyed 
by ESBLs (Crowley, Ratcliffe, 2003; Tumbarello et al., 
2004; Rossi et al., 2006). Although there are no CLSI rec-
ommendations for the detection of ESBL in Enterobacter 
spp., the present study demonstrated the importance to 
detect this kind of enzyme also in this genus, since 13.4% 
of the isolates were ESBL positive.
In the case of P. mirabilis, CLSI recommends ESBL 
screening tests only when it is clinically relevant, as a 
bacteremic isolate. At LEPAC, any lower sensitivity was 
investigated, even in less noble clinical specimens; even 
though, only 2 ESBL-producing bacteria were found 
among a total of 28 isolates: one was isolated from a 
pleural fluid sample from a patient in the general unit and 
the other was from an operated wound from a patient who 
had returned to the ER. This generated a prevalence of 
7.1%, as observed in other studies in Brazil (Peloso et al., 
2003; Nogueira et al., 2006) and in other Latin American 
countries (Dalmarco et al., 2006). 
Although CLSI recommends the detection of ESBL 
only for K. pneumoniae, K. oxytoca, E. coli, and occasion-
ally P. mirabilis, it is known that other genera from the 
Enterobacteriaceae family, such as Shigella, Morganella, 
Citrobacter, and Serratia, may carry ESBL coding genes 
(Bonnet, 2004). It is thus important to look out for lower 
sensitivity levels to cephalosporins in other species, with 
particular attention to hospitalized patients. Reports of 
ESBL production in other CLSI’s non-recommended 
Enterobacteriaceae species demonstrate the need to 
standardize detection techniques for this enzyme in other 
bacteria too.
Clinical results show that, when third-generation 
cephalosporins in ESBL-producing bacteria are used, a 
better evaluation is required, due to the alteration in sus-
ceptibility breakpoints for these antimicrobial substances.
With regard to DNA analysis of ESBL positive 
isolates, it is interesting to find out whether the high 
prevalence reported in the present study was due to the 
dissemination of one or a few mutant clones, or whether 
it was due to an individual selection of resistant strains.
CONCLUSION
Epidemiological studies similar to the present one 
turn out to be important to evaluate an institution’s lo-
cal status and to formulate a policy of empiric therapy. 
Although HUM is considered a small-sized hospital, it 
presents high levels of antimicrobial resistance, similar 
to those observed in bigger hospitals; therefore, care-
ful epidemiological surveillance is clearly mandatory. 
Unfortunately, that may also be the case of many other 
Brazilian hospitals.
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